[{"orgOrder":0,"company":"Fresh Tracks Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"BBI-02","moa":"DYRK1A","graph1":"Dermatology","graph2":"Phase I","graph3":"Fresh Tracks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Fresh Tracks Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Fresh Tracks Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Fresh Tracks Therapeutics","sponsor":"Syneos Health | Innovaderm","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"FRTX-02","moa":"DYRK1A","graph1":"Dermatology","graph2":"Phase I","graph3":"Fresh Tracks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Fresh Tracks Therapeutics \/ Syneos Health | Innovaderm","highestDevelopmentStatusID":"6","companyTruncated":"Fresh Tracks Therapeutics \/ Syneos Health | Innovaderm"},{"orgOrder":0,"company":"Fresh Tracks Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"FRTX-02","moa":"DYRK1A","graph1":"Dermatology","graph2":"Phase I","graph3":"Fresh Tracks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Fresh Tracks Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Fresh Tracks Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Fresh Tracks Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"FRTX-02","moa":"DYRK1A","graph1":"Dermatology","graph2":"Phase I","graph3":"Fresh Tracks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Fresh Tracks Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Fresh Tracks Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Fresh Tracks Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"FRTX-02","moa":"DYRK1A","graph1":"Dermatology","graph2":"Phase I","graph3":"Fresh Tracks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Fresh Tracks Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Fresh Tracks Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Fresh Tracks Therapeutics","sponsor":"Kaken Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Sofpironium Bromide","moa":"Muscarinic acetylcholine receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Fresh Tracks Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Fresh Tracks Therapeutics \/ Fresh Tracks Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Fresh Tracks Therapeutics \/ Fresh Tracks Therapeutics"},{"orgOrder":0,"company":"Fresh Tracks Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Sofpironium Bromide","moa":"Muscarinic acetylcholine receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Fresh Tracks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Fresh Tracks Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Fresh Tracks Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Fresh Tracks Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Sofpironium Bromide","moa":"Muscarinic acetylcholine receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Fresh Tracks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Fresh Tracks Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Fresh Tracks Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Fresh Tracks Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Sofpironium Bromide","moa":"Muscarinic acetylcholine receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Fresh Tracks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Fresh Tracks Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Fresh Tracks Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Fresh Tracks Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sofpironium Bromide","moa":"Muscarinic acetylcholine receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Fresh Tracks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Fresh Tracks Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Fresh Tracks Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Fresh Tracks Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Sofpironium Bromide","moa":"Muscarinic acetylcholine receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Fresh Tracks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Fresh Tracks Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Fresh Tracks Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Fresh Tracks Therapeutics","sponsor":"Botanix Pharma","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Agreement","leadProduct":"Sofpironium Bromide","moa":"Muscarinic acetylcholine receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Fresh Tracks Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0.01,"dosageForm":"Gel","sponsorNew":"Fresh Tracks Therapeutics \/ Botanix Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Fresh Tracks Therapeutics \/ Botanix Pharma"},{"orgOrder":0,"company":"Fresh Tracks Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Public Offering","leadProduct":"Sofpironium Bromide","moa":"Muscarinic acetylcholine receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Fresh Tracks Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0.01,"dosageForm":"Gel","sponsorNew":"Fresh Tracks Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Fresh Tracks Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Fresh Tracks Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sofpironium Bromide","moa":"Muscarinic acetylcholine receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Fresh Tracks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Fresh Tracks Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Fresh Tracks Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Fresh Tracks Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sofpironium Bromide","moa":"Muscarinic acetylcholine receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Fresh Tracks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Fresh Tracks Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Fresh Tracks Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Fresh Tracks Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Sofpironium Bromide","moa":"Muscarinic acetylcholine receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Fresh Tracks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Fresh Tracks Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Fresh Tracks Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Fresh Tracks Therapeutics","sponsor":"Kaken Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Sofpironium Bromide","moa":"Muscarinic acetylcholine receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Fresh Tracks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Fresh Tracks Therapeutics \/ Kaken Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Fresh Tracks Therapeutics \/ Kaken Pharmaceuticals"},{"orgOrder":0,"company":"Fresh Tracks Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Sofpironium Bromide","moa":"Muscarinic acetylcholine receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Fresh Tracks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Fresh Tracks Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Fresh Tracks Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Fresh Tracks Therapeutics","sponsor":"Bodor Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"Sofpironium Bromide","moa":"Muscarinic acetylcholine receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Fresh Tracks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Fresh Tracks Therapeutics \/ Fresh Tracks Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Fresh Tracks Therapeutics \/ Fresh Tracks Therapeutics"},{"orgOrder":0,"company":"Fresh Tracks Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"BBI-5000","moa":"Prostaglandin D2 receptor 2 (PTGDR2)","graph1":"Dermatology","graph2":"Phase I","graph3":"Fresh Tracks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fresh Tracks Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Fresh Tracks Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Fresh Tracks Therapeutics","sponsor":"AnGes","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"AG0302-COVID-19","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Fresh Tracks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fresh Tracks Therapeutics \/ Fresh Tracks Therapeutics","highestDevelopmentStatusID":"9","companyTruncated":"Fresh Tracks Therapeutics \/ Fresh Tracks Therapeutics"},{"orgOrder":0,"company":"Fresh Tracks Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"BBI-2000","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"Fresh Tracks Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fresh Tracks Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Fresh Tracks Therapeutics \/ Undisclosed"}]
Find Clinical Drug Pipeline Developments & Deals by Brickell Biotech
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
